At the Heart of Innovation

CardiaTec is applying artificial intelligence on large-scale multi-omic data to develop the next generation of cardiovascular disease drug targets

Cardiovascular Disease

The Leading Global Cause of Death

Cardiovascular disease has been the leading global cause of death since the 1970s and claims over 17 million lives each year - to put this into perspective, every minute some dies from a cardiovascular event.

Despite its impact, research & development in the cardiovascular field has been massively underfunded compared to other indications, such as cancer and neurodegenerative disease. This has resulted in a stagnation of novel therapeutic innovation and a large unmet need for patients. As a result, there is a strong requirement for new efforts to help close the increasingly growing gap.

Our Approach

Target Discovery

Drug Discovery

Personalised Medicine

CardiaTec’s AI driven multi-omics analysis platform can unravel relationships that span across every layer of biology, from gene variation, methylation and expression, to their connection to proteomic and metabolomic functions. This serves to help uncover the next generation of cardiovascular disease drug targets with highly explainable biological function.

CardiaTec is exploring computationally enabled target-drug interactions to support the development of novel drugs into the clinic. CardiaTec's approach puts biology first for more informed drug discovery and is fully modality agnostic.

CardiaTec is exploring patient stratification and biomarker identification to define patient endotypes most compatible to novel therapeutics to maximise patient benefit. This serves to facilitate the transition into the next paradigm of personalised medicine for cardiovascular disease, differentiating from the current one-size-fits-all standards of care.

TEAM

Meet The Team

CardiaTec spun-out of the University of Cambridge in September 2021, led by Professor Namshik Han, a world leading expert in AI for Drug Discovery and Raphael Peralta & Thelma Zablocki, alumni of the MPhil Bioscience Enterprise. Alongside them, CardiaTec’s team is composed of talented individuals underpinned by decades of computational drug discovery and industry expertise.